The North America Multiple Myeloma Market would witness market growth of 8.6% CAGR during the forecast period (2023-2029).
The increased prevalence of multiple myeloma, an increase in the number of market players who produce multiple myeloma pharmaceuticals, and an increase in the number of product releases for multiple myeloma drugs are the main factors driving the growth of the market. Multiple myeloma is often called Kahler's disease. The blood and bones were exposed to excessive protein. Organ damage results from its accumulation throughout the body.
One of the main types of blood cancer that accounts for a sizable portion of cases of cancer is multiple myeloma (MM), despite being regarded as an uncommon form of cancer. More patients are diagnosed with their ailment due to growing awareness of disease signs. Increased treatment sophistication by key market players has resulted in several successful and potentially successful medications being released. In diagnosed patients, death could result from untreated conditions. Due to unmet clinical requirements and the growing demand for effective treatment outcomes, market players are conducting a large number of clinical studies for the introduction of new therapies.
According to the International Agency for Research on Cancer, there were 35318 new cases of multiple myeloma registered in the region in 2020. According to the American Cancer Society, the US saw almost 24,050 new instances of multiple myeloma at the end of 2014. In this region, age-related increases in the frequency of multiple myelomas are more common in males than women. Thus, a rise in the older population would surely fuel the demand for therapies for multiple myeloma. Thus, the important factors anticipated to accelerate the expansion of the market for multiple myeloma are the increasing occurrence of the condition and the rise in the senior population. Thus, the market in the North America will increase significantly in the coming years.
The US market dominated the North America Multiple Myeloma Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $10,505.2 Million by 2029. The Canada market is poised to grow at a CAGR of 10.7% during (2023 - 2029). Additionally, The Mexico market would witness a CAGR of 10.4% during (2023 - 2029).
Based on End User, the market is segmented into Hospitals, Clinics, and Others. Based on Disease Type, the market is segmented into Active Multiple Myeloma and Smoldering Multiple Myeloma. Based on Drug Type, the market is segmented into Protease Inhibitors, Monoclonal Antibody, Chemotherapy and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Multiple Myeloma Market is Projected to reach USD 37.5 Billion by 2029, at a CAGR of 9.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Bristol Myers Squibb Company, Amgen, Inc., AbbVie, Inc., Sanofi S.A., Johnson & Johnson, Baxter International, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc.
By End User
By Disease Type
By Drug Type
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 